GlassScriptPhysician profile
Chaelyn Tani
NPI 1063221455
$2,335.96
in general payments reported to CMS, 2019-2025
21 companies · $2,158 in 2025
The $2,158 reported for 2025 was more than what 94% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $178 · 2025: $2,158.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,038 · Education: $298.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,037.97 |
| Education | $297.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $403.52 | 2024-2025 | Darzalex, Tecvayli, Talvey |
| Incyte Corporation | $256.74 | 2025 | Jakafi, Niktimvo, Monjuvi |
| Astrazeneca Pharmaceuticals LP | $200.18 | 2025 | Imfinzi, Lynparza |
| Takeda Pharmaceuticals U.S.A., INC. | $184.65 | 2025 | Ninlaro |
| Novartis Pharmaceuticals Corporation | $184.20 | 2025 | |
| Merck Sharp & Dohme LLC | $161.37 | 2025 | Keytruda, Keytruda Qlex |
| E.R. Squibb & Sons, L.L.C. | $148.39 | 2025 | Opdivo |
| Amgen INC. | $147.74 | 2025 | Imdelltra (Amg757), Lumakras |
| Exelixis INC. | $126.51 | 2025 | Cabometyx |
| Seagen INC. | $99.99 | 2025 | |
| Eisai INC. | $83.21 | 2025 | |
| Pfizer INC. | $63.30 | 2025 | |
| Abbvie INC. | $53.20 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $46.83 | 2025 | |
| Genentech USA, INC. | $38.35 | 2025 | Tecentriq, Venclexta |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $25.57 | 2025 | Barrigel |
| Emd Serono, INC. | $25.51 | 2025 | |
| Kyowa Kirin, INC. | $24.17 | 2025 | |
| Astellas Pharma US INC | $24.06 | 2025 | Xtandi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.75 | 2025 | |
| Novo Nordisk INC | $17.72 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chaelyn Tani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.